Allovate, LLC is a specialty biopharmaceutical company that is developing an improved approach to allergen-specific immunotherapy for the treatment of allergic diseases. Allergic diseases affect more than 25% of the global industrial population, at an annual cost in excess of $33 billion in the US alone. There is an enormous and growing unmet need